CN118076342B - 用于缓激肽b2受体拮抗剂的口服给药的脂质基组合物 - Google Patents
用于缓激肽b2受体拮抗剂的口服给药的脂质基组合物Info
- Publication number
- CN118076342B CN118076342B CN202280067108.5A CN202280067108A CN118076342B CN 118076342 B CN118076342 B CN 118076342B CN 202280067108 A CN202280067108 A CN 202280067108A CN 118076342 B CN118076342 B CN 118076342B
- Authority
- CN
- China
- Prior art keywords
- propylene glycol
- pharmaceutical composition
- liquid
- liquid pharmaceutical
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21189990 | 2021-08-05 | ||
| EP21189990.1 | 2021-08-05 | ||
| PCT/EP2022/072049 WO2023012322A1 (en) | 2021-08-05 | 2022-08-05 | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118076342A CN118076342A (zh) | 2024-05-24 |
| CN118076342B true CN118076342B (zh) | 2025-08-05 |
Family
ID=77226756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280067108.5A Active CN118076342B (zh) | 2021-08-05 | 2022-08-05 | 用于缓激肽b2受体拮抗剂的口服给药的脂质基组合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20240350418A1 (https=) |
| EP (1) | EP4203919B1 (https=) |
| JP (1) | JP2024528195A (https=) |
| KR (1) | KR20240039185A (https=) |
| CN (1) | CN118076342B (https=) |
| AU (1) | AU2022323749A1 (https=) |
| BR (1) | BR112024002215A2 (https=) |
| CA (1) | CA3227476A1 (https=) |
| CO (1) | CO2024001171A2 (https=) |
| DK (1) | DK4203919T3 (https=) |
| ES (1) | ES2978563T3 (https=) |
| FI (1) | FI4203919T3 (https=) |
| HR (1) | HRP20240525T1 (https=) |
| HU (1) | HUE066306T2 (https=) |
| IL (1) | IL310321A (https=) |
| LT (1) | LT4203919T (https=) |
| MA (1) | MA61123B1 (https=) |
| MX (1) | MX2024001711A (https=) |
| PL (1) | PL4203919T3 (https=) |
| PT (1) | PT4203919T (https=) |
| RS (1) | RS65427B1 (https=) |
| SI (1) | SI4203919T1 (https=) |
| SM (1) | SMT202400157T1 (https=) |
| WO (1) | WO2023012322A1 (https=) |
| ZA (1) | ZA202401504B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117224522B (zh) * | 2023-11-15 | 2024-02-23 | 北京协和药厂有限公司 | 药物组合物及其制备方法、药物制剂 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008055146A2 (en) * | 2006-10-31 | 2008-05-08 | Wyeth | Formulations of phospholipase enzyme inhibitors |
| WO2019101906A1 (en) * | 2017-11-24 | 2019-05-31 | Pharvaris B.V. | Novel bradykinin b2 receptor antagonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2218554T3 (es) | 1994-10-27 | 2004-11-16 | Fujisawa Pharmaceutical Co., Ltd. | Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina. |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| JP2002517461A (ja) | 1998-06-08 | 2002-06-18 | アドバンスド メディスン インコーポレーテッド | ブラジキニンアンタゴニスト |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| WO2014159637A1 (en) | 2013-03-14 | 2014-10-02 | Shire Human Genetic Therapies, Inc. | Methods of treating b2-bradykinin receptor mediated angioedema |
-
2022
- 2022-08-05 MA MA61123A patent/MA61123B1/fr unknown
- 2022-08-05 IL IL310321A patent/IL310321A/en unknown
- 2022-08-05 KR KR1020247007280A patent/KR20240039185A/ko active Pending
- 2022-08-05 CN CN202280067108.5A patent/CN118076342B/zh active Active
- 2022-08-05 PT PT227609864T patent/PT4203919T/pt unknown
- 2022-08-05 HU HUE22760986A patent/HUE066306T2/hu unknown
- 2022-08-05 BR BR112024002215A patent/BR112024002215A2/pt unknown
- 2022-08-05 ES ES22760986T patent/ES2978563T3/es active Active
- 2022-08-05 FI FIEP22760986.4T patent/FI4203919T3/fi active
- 2022-08-05 AU AU2022323749A patent/AU2022323749A1/en active Pending
- 2022-08-05 SM SM20240157T patent/SMT202400157T1/it unknown
- 2022-08-05 SI SI202230031T patent/SI4203919T1/sl unknown
- 2022-08-05 CA CA3227476A patent/CA3227476A1/en active Pending
- 2022-08-05 RS RS20240456A patent/RS65427B1/sr unknown
- 2022-08-05 EP EP22760986.4A patent/EP4203919B1/en active Active
- 2022-08-05 PL PL22760986.4T patent/PL4203919T3/pl unknown
- 2022-08-05 LT LTEPPCT/EP2022/072049T patent/LT4203919T/lt unknown
- 2022-08-05 DK DK22760986.4T patent/DK4203919T3/da active
- 2022-08-05 MX MX2024001711A patent/MX2024001711A/es unknown
- 2022-08-05 WO PCT/EP2022/072049 patent/WO2023012322A1/en not_active Ceased
- 2022-08-05 HR HRP20240525TT patent/HRP20240525T1/hr unknown
- 2022-08-05 US US18/681,298 patent/US20240350418A1/en active Pending
- 2022-08-05 JP JP2024506610A patent/JP2024528195A/ja active Pending
-
2024
- 2024-02-05 CO CONC2024/0001171A patent/CO2024001171A2/es unknown
- 2024-02-20 ZA ZA2024/01504A patent/ZA202401504B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008055146A2 (en) * | 2006-10-31 | 2008-05-08 | Wyeth | Formulations of phospholipase enzyme inhibitors |
| WO2019101906A1 (en) * | 2017-11-24 | 2019-05-31 | Pharvaris B.V. | Novel bradykinin b2 receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2978563T3 (es) | 2024-09-16 |
| PL4203919T3 (pl) | 2024-06-10 |
| FI4203919T3 (fi) | 2024-05-03 |
| KR20240039185A (ko) | 2024-03-26 |
| SI4203919T1 (sl) | 2024-08-30 |
| RS65427B1 (sr) | 2024-05-31 |
| US20240350418A1 (en) | 2024-10-24 |
| PT4203919T (pt) | 2024-04-23 |
| EP4203919A1 (en) | 2023-07-05 |
| EP4203919B1 (en) | 2024-01-31 |
| HUE066306T2 (hu) | 2024-07-28 |
| ZA202401504B (en) | 2025-06-25 |
| MA61123B1 (fr) | 2024-06-28 |
| CA3227476A1 (en) | 2023-02-09 |
| CO2024001171A2 (es) | 2024-05-20 |
| CN118076342A (zh) | 2024-05-24 |
| JP2024528195A (ja) | 2024-07-26 |
| AU2022323749A1 (en) | 2024-02-08 |
| DK4203919T3 (da) | 2024-04-29 |
| BR112024002215A2 (pt) | 2024-04-30 |
| SMT202400157T1 (it) | 2024-05-14 |
| IL310321A (en) | 2024-03-01 |
| WO2023012322A1 (en) | 2023-02-09 |
| MX2024001711A (es) | 2024-03-05 |
| TW202320774A (zh) | 2023-06-01 |
| LT4203919T (lt) | 2024-05-10 |
| HRP20240525T1 (hr) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102593075B1 (ko) | 셀렉시파그를 포함하는 약학 조성물 | |
| ES2892029T3 (es) | Formulaciones de enzalutamida | |
| ES2231717T3 (es) | Forma de dosificacion farmaceutica del mesilato de melfinavir amorfo. | |
| ES2226976T3 (es) | Formulaciones galenicas de fenofibrato y su procedimiento de obtencion. | |
| TW201114766A (en) | Pharmaceutical composition for a hepatitis C viral protease inhibitor | |
| JP2015516418A (ja) | １，１−ジメチルエチル［（１ｓ）−１−｛［（２ｓ，４ｒ）−４−（７−クロロ−４メトキシイソキノリン−１−イルオキシ）−２−（｛（１ｒ，２ｓ）−１−［（シクロプロピルスルホニル）カルバモイル］−２−エテニルシクロプロピル｝カルバモイル）ピロリジン−１−イル］カルボニル｝−２，２−ジメチルプロピル］カルバメートの可溶化カプセル製剤 | |
| JP2023520273A (ja) | 治療化合物、製剤、およびその使用 | |
| CN118076342B (zh) | 用于缓激肽b2受体拮抗剂的口服给药的脂质基组合物 | |
| BR112019014712A2 (pt) | Tratamento médio que compreende a administração entérica de edaravona | |
| CN110237031A (zh) | 包含释放一氧化氮的前列酰胺的眼用组合物 | |
| US20120213855A1 (en) | Dosage forms for weakly ionizable compounds | |
| ES2235765T3 (es) | Composiciones farmaceuticas que comprenden ciclosporina como ingredientes activos. | |
| WO2008087076A1 (en) | Pharmaceutical composition of improved stability containing taxane derivatives | |
| KR20000069308A (ko) | Ｎ-설포닐인돌린 유도체를 포함하는 약학적 조성물 | |
| ES3062067T3 (en) | Solid composition comprising solubilised bradykinin b2-receptor antagonists | |
| JP6014252B2 (ja) | ネパデュタントを含有する小児用経口液体組成物 | |
| HK40088043B (en) | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists | |
| HK40088043A (en) | Lipid-based composition for oral administration of bradykinin b2-receptor antagonists | |
| US20200368221A1 (en) | Solid particle, preparation method therefor, and pharmaceutical composition containing solid particle | |
| EA051972B1 (ru) | Композиция на основе липидов для перорального применения антагонистов брадикининовых b2-рецепторов | |
| JP2026505949A (ja) | 自己乳化医薬組成物、その製造方法及び使用 | |
| JP2011084521A (ja) | アゼラスチン塩酸塩含有カプセル剤 | |
| TW202135806A (zh) | 含西羅莫司(sirolimus)或其鹽之水性懸浮組合物 | |
| WO2013062497A1 (en) | Liquid pharmaceutical formulations | |
| JP5171143B2 (ja) | 用時溶解型ビタミン製剤及びその製造方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |